Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Alzheimer’s Drugs Market Grown from 2024 to 2025?

The market size for Alzheimer’s drugs has experienced robust growth in the past few years. The market is projected to expand from $9.33 billion in 2024 to $10.19 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. The increase in the number of Alzheimer’s disease incidents, investment in research and development, better comprehension of the disease mechanism, worldwide health programs, and public consciousness and education are all contributing to the historical growth.

What Growth Rate Is Anticipated for the Alzheimer’s Drugs Market in the Coming Years?

In the forthcoming years, a robust growth is anticipated in the Alzheimer’s drugs market, projected to expand to $14.47 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 9.2%. The escalation in the predicted time frame is linked to precision medicine techniques, emphasis on disease alteration, detection and validation of biomarkers, patient-focused drug creation, and concentration on non-pharmacological measures. The forecast period will also see prevalent trends such as varied therapeutic approaches, digital health advancements, regenerative medicine, progress in diagnostic technologies, the deployment of Artificial Intelligence (AI) in drug discovery, and strategic partnerships and collaborations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

Who Are the Leading Companies in the Alzheimer’s Drugs Market?

Major companies operating in the alzheimer’s drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd

What Are the Key Drivers of the Alzheimer’s Drugs Market?

The anticipated increase in Alzheimer’s disease cases is predicted to fuel the expansion of the Alzheimer’s drugs market in the future. Characterized by progressive neurological deterioration resulting in brain atrophy and cell death, Alzheimer’s disease uses specific drugs to address symptoms such as memory loss, cognitive difficulties, and daily living struggles. These Alzheimer’s drugs can improve life quality and aid in maintaining independence. For example, a report from the Alzheimer’s Association, a US-based nonprofit committed to Alzheimer’s treatment, support, and research, noted that the count of Americans aged 65 or older with Alzheimer’s dementia went up from 6.5 million in 2022 to a projected 6.9 million in May 2024. Consequently, the rising incidence of Alzheimer’s disease is the driving force behind the Alzheimer’s drugs market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp

What Are the Key Market Segments in the Alzheimer’s Drugs Industry?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Subsegments:

1) By Donepezil: Oral Tablets, Oral Solution

2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches

3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules

4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules

What Are the Latest Trends in the Alzheimer’s Drugs Market?

Leading entities within the Alzheimer’s drug market are working towards inventing innovative products, such as therapy targeting amyloid plaques, to enhance treatment possibilities and promote better patient outcomes. The therapy focusing on amyloid plaques is a crucial approach for treating Alzheimer’s disease and aims to inhibit or decrease the amyloid-beta plaques accumulation in the brain. For example, in June 2024, the US-based pharmaceutical corporation, Eli Lilly and Company, received FDA clearance for Kisunla (donanemab-azbt). Kisunla (donanemab-azbt) is the first of its kind therapy targeting amyloid plaques for early symptomatic Alzheimer’s disease. It functions by assisting the body in eliminating the surplus amyloid plaques from the brain, responsible for cognitive deterioration in Alzheimer’s patients. Administered every four weeks via an intravenous infusion, Kisunla initially demands a 700 mg regimen for the first three doses, which then increases to 1400 mg. Kisunla is specifically recommended for adults diagnosed with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, conditional on confirmed amyloid pathology.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

What Are the Key Regional Markets in the Alzheimer’s Drugs Industry?

North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9040

This Report Delivers Insight On:

1. How big is the alzheimer’s drugs market, and how is it changing globally?

2. Who are the major companies in the alzheimer’s drugs market, and how are they performing?

3. What are the key opportunities and risks in the alzheimer’s drugs market right now?

4. Which products or customer segments are growing the most in the alzheimer’s drugs market?

5. What factors are helping or slowing down the growth of the alzheimer’s drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model